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A B S T R A C T
Axillary management in breast cancer is still controversial. Recent clinical trials have clearly demonstrated that
in breast-conserving surgery, axillary dissection could be an overtreatment whenmetastases are present in only
1–2 sentinel lymph nodes. Nonetheless, axillary dissection remains the principal treatment in patients
undergoing mastectomy with at least one metastatic sentinel lymph node and in patients eligible for breast
conserving surgery with three or more positive sentinel lymph nodes.
In this analytical review, we discuss the clinical evidence, taking into account recent guidelines, for axillary
management.
© 2019 Elsevier Ltd. All rights reserved.
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Introduction
For more than one hundred years, axillary lymph node dissection
(ALND) has been the gold standard treatment for breast cancer (BC)
care and management. Firstly, breast tumor was considered as a
loco-regional disease, which spread through lymphatic system,
and ALND was the unique life-saving option in BC patients. In 1977,
the NSABP B04 randomized trial demonstrated that BC survival
was independently associatedwith loco-regional treatments (with or
without ALND) in cN0 patients [1]. ALND was, and still is, a clinical
burden due to the frequent high morbidity such as lymphedema,
pain, nerve damage, etc. In 1990, the introduction into clinical
practice of sentinel lymph node biopsy (SNB) [2] significantly
reduced these problematic scenarios without impact on long-term
survival [3]. In particular ALND can be avoided in cases of
histologically negative SNB. Currently, SNB is considered the standard
treatment for BC cancer care in patientswith clinically negative axilla,
as well as in breast conserving surgery and in mastectomy.
Inflammatory BC remains a contraindication for SNB.
However, the results from several recent clinical trials have raised
the questions: Could ALND be avoided in certain cases of metastatic
SNB? Could SNB be avoided when the axillary examination is
clinically negative?
In this brief review, we set out, on the basis of current scientific
evidence and our own experience, to answer these questions and
provide recommendations for or against ALND.
Breast-conserving surgery
The American College of Surgeons Oncology Group randomized
clinical trial Z0011 (ACOSOG Z0011) was designed to evaluate
whether SNB alone impacts on survival outcomes compared to
ALND in breast-conserving surgery (BCS) [4]. This initial trial enrolled
women with clinical T1–T2 invasive BC, non-palpable adenopathy,
and 1–2 SNs containing metastases. Patients were randomized to
ALND (445) or SNB alone (446), following whole-breast irradiation
and adjuvant treatments.
The early results demonstrated no difference in locoregional
recurrence for patients with positive SNs randomized to either
ALND or SNB alone.
Further, long-term locoregional recurrence results demonstrated
that at a median follow-up of 9.25 years, there was no statistically
significant difference in local recurrence-free survival (p = 0.13). The
cumulative incidence of nodal recurrences at 10 years was 0.5% in the
ALND arm and 1.5% in the SNB alone arm (p = 0.28). Ten-year
cumulative locoregional recurrence was 6.2% with ALND and 5.3%
with SNB alone (p = 0.36) [5].
In line with the ACOSOG Z0011 trial results, the current surgical
indication in BCS does not justify ALND in T1-T2 BC with only 1-2
positive SNs. Conversely, if ≥3 SNs exhibit metastases, or a
macroscopic LN is found intraoperatively, then ALND is still strongly
recommended.
Following on from the ACOSOG Z0011 trial results, the AMAROS
trial (After Mapping of the Axilla: Radiotherapy Or Surgery), a
randomised, multicentre, open-label, phase 3 non-inferiority trial,
demonstrated that in patients with T1-T2 primary BC, ALND and
axillary radiotherapy after a positive SN provide excellent and
comparable axillary control. Moreover, axillary radiotherapy
results in significantly less morbidity [6], with a lower risk of
lymphedema.
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Of course, these results don’t mean that all patients with positive
sentinel node need axillary radiotherapy, since similar excellent
outcomes were described in ACOSOG Z0011 in the absence of
axillary treatment [4]. In particular, selective node radiotherapy is
indicated in a sub-group of high-risk patients with only 1-2 SNs with
metastases: 1) large tumor (≥3 cm); 2) lymphovascular tumor
invasion; 3) microscopic extracapsular extension of metastases in
SNs [7].
We have observed at the European Institute of Oncology 1.386
consecutive cT1-2N0 BC patients (2016–2018), eligible for BCS. SN
biopsy resulted respectively negative in 1.156 (83,4%) and positive in
230 (16,6%) patients. Seven out of these 230 patients (3.0%) were
admitted at complete ALND, and 233 (97.0%) were observed. In the
ALND group a total of 155 lymphnodeswere removed and 17 resulted
metastatic at histopathologic examination. Results about overall
survival, disease free survival and breast specific survival are under
consideration.
Mastectomy
Histopathological classification of SN defines three distinct subtypes:
1) macrometastases (>2 mm), 2) micrometastatic foci (≤2 mm), and
3) isolated tumor cells.
For patients undergoing mastectomy, ALND still represents the
standard treatment in cases of macrometastases to the SN. Currently
there is no evidence to suggest against this strategy. However there
are ongoing clinical trials on this topic.
Currently, in the case of SN with micrometastasis and/or isolated
tumor cells, ALND is not indicated and probably represents
overtreatment.
In the IBCSG 23-01 multicentre, randomised, non-inferiority,
phase 3 trial patients with a primary tumor of ≤5 cm and one or
more micrometastatic sentinel lymph node were randomly (in
patients eligible for mastectomy or BCS) assigned to ALND (465)
or no ALND (469). Median follow-up was 5 years; 5-year disease-
free survival was 87,8% (95% CI 84,4–91,2) in the group without
ALND and 84,4% (80,7–88,1) in the group with ALND (p = 0,16) [8].
Similar results were reported in the clinical trial AATRM048/13 [9].
The Authors concluded that for patients with limited sentinel-node
involvement, no axillary dissection is justified, provided that patients
receive both traditional whole breast radiation in BCS and systemic
adjuvant treatment.
These large trials clearly demonstrated that for patients with
micrometastatic sentinel-node involvement, axillary dissection is not
justified and this does not impact on survival, even in the absence of
radiotherapy.
Results from the IBCSG 23–01 trial regarding median follow-up of
10-years have recently been published. This study has confirmed that
no-ALND was not inferior to ALND with respect to disease-free
survival, without significant difference between the arms for disease-
free survival and overall survival, thus confirming that ALND is not
indicated in patients with micrometastatic SNs [10].
The SENOMAC trial is a new ongoing multicentric non-inferiority
study aimed at evaluating if “no axillary clearance in BC patients with
1-2 sentinel nodes with macrometastasis will not worsen breast
cancer-specific survival, both in conservative surgery and in
mastectomy.” The expected number of eligible patients is around
3,500 individuals. The estimated primary completion date will be
December 2022.
Neo-adjuvant treatments
The correct indication for SNB after neoadjuvant chemotherapy
(NAC) for BC is still controversial, particularly in patients with
clinically involved axilla before NAC that become clinically negative
after treatment (cN1>cN0).
The main indication for axillary clearance after neoadjuvant
therapy is represented by cases with cN1/2 axillary staging (clinical
examination or PET or axillary ultrasound) unchanged by treatment.
In a study from the European Institute of Oncology in Milan
involving 396 patients who were cT1-4 cN0/1/2 with negative
axillary staging after neoadjuvant treatment and who underwent
SNB and axillary clearance only in cases of metastatic SN, only one
case of axillary relapse was reported after a 61-month medium
follow-up [11].
Moreover, pre-operative lymphoscintigraphy to identify SNs,
contrary to common opinion and to some older studies, is a safe
and feasible procedure after neo-adjuvant therapies, independently
of treatment types [12].
These preliminary results suggest that SNB is a safe procedure for
cT1-T2 patients with negative axillary staging after neoadjuvant
treatment, particularly in cases with complete pathological response
on the breast of the primary lesion, SN status is significant for
prognosis and axillary clearance does not influence long-term
survival.
In addition, the 2017 St. Gallen consensus conference confirmed
SNB as the gold standard procedure for patients with negative
axillary staging (cN1/2>cN0) after neoadjuvant treatment, while
axillary clearance is still recommended if there is at least one
metatastatic node after NAC [13].
To date, there are some studies that confirm the feasibility of SN
biopsy alone after NAC treatment.
A recent meta-analysis, analysing a total of 13 studies, with a total
of 1921 patients with initial biopsy-proven node-positive BC,
demonstrated that SN biopsy after NAC is accurate and reliable with
careful patient selection and optimal surgical techniques [14].
A recent study by Classe and Colleagues (GANEA2) [15], enrolled
957 BC patients over 4 years (2010–2014), post NAC. There were two
groups: cN0 vs. pN1.
Among the 419 patients from the cN0 group treated with SN alone,
one axillary relapse occurred during the follow-up. Among pN1
group patients,103 had a negative SN. The FNRwas 11.9% (95% CI 7.3–
17.9%). For patientswith initially involved node, and negative SN after
NAC, the risk of a positive ALND is 3.7% regardless the number of SN
removed.
A recent prospective trial to assess the feasibility and efficacy of
placing clips into “most suspicious” biopsy-proven node followed 98
patients with axilla-positive locally advanced breast cancer (T1-4,
N1-3) [16]. The SN identification ratewas 87.8%. For the patients with
cN1 before NAC, the FNRwas found to be 4.2%when the clipped node
was identified as SN. However, the FNRwas estimated to be as high as
16.7% for the patients with cN1 before NAC when the clipped node
was found to be a non-SN. The study results suggest that axillary
dissection could be omitted for patients presenting initially with cN1
disease and with a negative clipped node as the SN after NAC due to
the low FNR.
In a retrospective study, Martelli and Colleagues [17] reported
overall survival, disease-free survival, and axillary failure in 317
consecutive cT2 cN0/1 patients given primary chemotherapy fol-
lowed by quadrantectomy or mastectomy. Axillary management was
classified into three groups: 101 (31.9%) given upfront axillary
dissection; 139 (43.8%) given SN biopsy plus axillary dissection;
and 77 (24.3%) given SN biopsy only because the SNs were negative.
Overall and disease free survival did not differ between these 3
groups, or between SN biopsy-only and the ypN1 and ypN0
subgroups of SN biopsy plus axillary dissection, or between the cN0
and cN1 subgroups (before chemotherapy) of the SN biopsy-only
group. No SN biopsy-only patient presented axillary failure.
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These abovementioned studies demonstrated that SN biopsy is
adequate in patients who are cN0 after primary chemotherapy,
irrespective of axillary status before.
“Observing” axillary lymphnodes
The ongoing SOUND (Sentinel node vs. Observation after axillary
Ultra-souND) trial is a prospective and randomized multicentric trial
[18–20] comparing SNB vs. no axillary surgical staging in patients
with small BC (tumor volume less than 2 cm of diameter) and
negative preoperative ultrasound of the axilla. In the case of single
doubtful lymph node on clinical and/or ultrasound examination and
negative, needle biopsy results the patient is still eligible. The primary
endpoint is distant disease-free survival, and the secondary endpoint
axillary disease-free survival, and quality of life.
A total of 1463womenwere included and 1,416were analyzed, 708
in each arm.Mean agewas 60 years andmean tumor sizewas 1.2 cm.
In the SLNB arm, micrometastases were detected in 36 (5.1%) and
macrometastases in 61 (8.6%) patients. To date the trial is closed, early
disease-free survival is under evaluation.
Conclusions
Evidently, there is a trend towards reducing surgical treatment of the
axilla in BC patients. The recent results, after 10 years of follow-up, of
the ACOSOG Z0011 trial, confirmed that ALND is not indicated in
positive SNBs (1-2 with metastases) [5], in patients eligible for BCS.
Similarly, in the case of mastectomy, the trial IBCSG 23-01 indicated
that ALND is an overtreatment in micrometastatic SNs [10].
SNB is also recommended in patients after neoadjuvant therapies,
in cases of initial cN0 and in cases of downgrading (cN1>N0). In node
positive (cN1) and palpable lymphnodes ALND remains the treat-
ment of choice (Figure 1) [13].
The initial SNB policy was no further axillary treatment if SNs were
negative. To date the new policy is changing to no additional axillary
surgery if SNs are positive. Axillary surgery, especially in the SNB
form, is still considered because the SNB status provides information
about the prognosis and does not influence the adjuvant treatments.
Histopathology of the primary tumor provides sufficient data for
defining adjuvant therapies. Thus, the SOUND trial was based initially
on this concept: avoid SNBwhilemaintaining primary breast surgery
[19–20].
In general, all results suggest that there are safe options
(observation, radiation therapy, systemic treatment) to avoid ALND
in selected subgroups of patients with SLN involvement.
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[16] Cabıoğlu N, Karanlık H, Kangal D, Özkurt E, Öner G, Sezen F, et al. Improved False-
Negative Rates with Intraoperative Identification of Clipped Nodes in Patients
Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy. Ann Surg
Oncol 2018;25:3030–3036. doi: 10.1245/s10434-018-6575-6.
[17] Martelli G, Miceli R, Folli S, Guzzetti E, Chifu C, Maugeri I, et al. Sentinel node biopsy
after primary chemotherapy in cT2 N0/1 breast cancer patients: Long-term results
of a retrospective study. Eur J Surg Oncol 2017;43:2012–2020. doi: 10.1016/j.ejso.
2017.07.023.
[18] https://clinicaltrials.gov/ct2/show/NCT02167490
[19] Gentilini O, Botteri E, Dadda P, Sangalli C, Boccardo C, Peradze N, et al. Physical function
of the upper limb after breast cancer surgery. Results from the SOUND (Sentinel node
vs. Observation after axillary Ultra-souND) trial. Eur J Surg Oncol 2016;42:685–9. doi:
10.1016/j.ejso.2016.01.020. Epub 2016 Feb 3.
[20] Gentilini O, Veronesi U. Abandoning sentinel lymphnode biopsy in early breast cancer?
A new trial in progress at the European Institute of Oncology ofMilan (SOUND: Sentinel
node vs Observation after axillary UltraSouND). Breast 2012;21:678–81. doi: 10.1016/j.
breast.2012.06.013. Epub 2012 Jul 25.
P. Veronesi and G. Corso / The Breast 48S1 (2019) S53–S56S56
